"Neoplasm Invasiveness" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
| Descriptor ID |
D009361
|
| MeSH Number(s) |
C04.697.645 C23.550.727.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Invasiveness".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Invasiveness".
This graph shows the total number of publications written about "Neoplasm Invasiveness" by people in this website by year, and whether "Neoplasm Invasiveness" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 10 | 10 |
| 2001 | 1 | 10 | 11 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 14 | 14 |
| 2004 | 2 | 6 | 8 |
| 2005 | 3 | 13 | 16 |
| 2006 | 1 | 13 | 14 |
| 2007 | 4 | 19 | 23 |
| 2008 | 4 | 22 | 26 |
| 2009 | 1 | 14 | 15 |
| 2010 | 0 | 16 | 16 |
| 2011 | 3 | 18 | 21 |
| 2012 | 1 | 17 | 18 |
| 2013 | 3 | 23 | 26 |
| 2014 | 3 | 21 | 24 |
| 2015 | 1 | 25 | 26 |
| 2016 | 2 | 27 | 29 |
| 2017 | 2 | 28 | 30 |
| 2018 | 0 | 15 | 15 |
| 2019 | 0 | 19 | 19 |
| 2020 | 0 | 15 | 15 |
| 2021 | 1 | 12 | 13 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 6 | 6 |
| 2024 | 2 | 7 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Invasiveness" by people in Profiles.
-
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Jan-Feb; 25(2):149-159.
-
Confined cell migration along extracellular matrix space in vivo. Proc Natl Acad Sci U S A. 2025 Jan 07; 122(1):e2414009121.
-
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu?rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Feb; 8(1):216-229.
-
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan; 31(1):176-188.
-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care. Expert Rev Anticancer Ther. 2024 Dec; 24(12):1203-1208.
-
Predicting Response to Intravesical Bacillus Calmette-Gu?rin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 Feb; 213(2):192-204.
-
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
-
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 09 01; 4(9):2444-2453.
-
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025 Feb; 135(2):260-268.